January 13, 2017 – Osimertinib
Podcast: Download (Duration: 1:05 — 1.5MB)
Anchor lead: A new treatment offers hope for people with non-small cell lung cancer, Elizabeth Tracey reports
A new type of therapy for people with non-small lung cancer, which has historically been very hard to treat, has shown quite promising results, a study in the New England Journal of Medicine shows. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, describes the results.
Nelson: The osimertinib did very well. Progression-free survival was improved dramatically the response rate was 71% of the tumors shrunk more with the osimertinib versus only 31% with the chemotherapy combination and the high grade toxicities were less, so this is clearly a drug that is going to be part of the arsenal to treat this kind of non-small cell lung cancer. :23
Nelson says osimertinib targets a known problem in many with this disease.
Nelson: You knew that this receptor was the driver, and yet you couldn’t stop this particular mutant from working and so now that you can I think it opens up the ability to treat many more people. :09
At Johns Hopkins, I’m Elizabeth Tracey.